A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 11, 2015

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2019

Conditions
Pediatric Solid TumorRefractory TumorRecurrent TumorCNS Malignancies
Interventions
DRUG

Ramucirumab

Administered IV

Trial Locations (21)

10032

Columbia University Medical Center, New York

15224

Childrens Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20892

Mark O Harfield-Warren Grant Magnuson Clinical Center, Bethesda

30322

Children's Healthcare of Atlanta at Scottish Rite, Atlanta

35233

Childrens Hospital of Alabama, Birmingham

38105

St Jude Childrens Research Hospital, Memphis

46202

Riley Hospital for Children, Indianapolis

48109

University of Michigan Health Systems, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota Hospital, Minneapolis

60611

Ann & Robert H Lurie Children's Hospital of Chicago, Chicago

63110

Washington University Medical School, St Louis

77030

Texas Childrens Hospital, Houston

91016

Children's Oncology Group, Monrovia

92868

Childrens Hospital of Orange County, Orange

94158

University of California, San Francisco, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital Research Foundation, Seattle

20010-2970

Children's National Medical Center, Washington D.C.

45229-3039

Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

Children's Oncology Group

NETWORK

lead

Eli Lilly and Company

INDUSTRY

NCT02564198 - A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter